For patients with lung adenocarcinoma IIIa in the presence of a gene mutation, it is usually appropriate to take the targeted drug one month after surgery. If no gene mutation is detected, it is not necessary to take it.
It is not possible to generalize how long to take targeted drugs after lung adenocarcinoma IIIa surgery. Genetic test is needed before taking drugs, and only those who have clear gene mutation can take targeted drug treatment.
Generally speaking, it is appropriate to take targeted drugs about one month after surgery. For those with EGFR gene mutation, they can take drugs such as gefitinib, erlotinib, afatinib, etc.; for those with ALK gene rearrangement, they can take targeted drugs such as crizotinib, alectinib, ceritinib, etc. If the patient does not have gene mutation, he/she can take targeted drugs.
If patients do not have gene mutation, they do not need to take targeted drugs, and even if they take them, they will not be able to play an efficient role, so they can consider adopting chemotherapy, radiotherapy and other modes of treatment to enhance the therapeutic effect.
It is suggested that patients with lung adenocarcinoma IIIa should choose appropriate treatment according to their personal situation, and should not use drugs by themselves.